Tesamorelin 5mg + Ipamorelin 5mg

Description

This blend combines two complementary growth hormone–releasing peptides—Tesamorelin and Ipamorelin—intended for preclinical research exploring GH-axis modulation with dual receptor activation mechanisms.

• Tesamorelin is a synthetic 44–amino-acid GHRH analogue, N-terminally modified with trans‑3‑hexenoic acid. It targets GHRH receptors in the pituitary, promoting endogenous, pulsatile GH secretion and used in research on metabolism, body composition, and endocrine signaling [1].
• Ipamorelin is a selective ghrelin receptor (GHS‑R1a) agonist, a pentapeptide that induces GH release without affecting cortisol or prolactin levels, supporting investigation into GH pulsation, metabolism, and anabolic processes [2][3].

When used together, Tesamorelin initiates GH-axis activation via GHRH receptor pathways, while Ipamorelin amplifies GH release through ghrelin receptor stimulation. This dual-mechanism approach enables robust GH secretion in research frameworks, supporting studies into metabolic regulation, tissue repair, and neuroendocrine function.